Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public

#AVDL Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes

www.stocktitan.net/news/AVDL/avadel-pharmac...

Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia Avadel Pharmaceuticals (Nasdaq: AVDL) announced completion of patient enrollment in REVITALYZ, a Phase 3 randomized withdrawal trial of LUMRYZ (sodium oxybate) extended-release for idiopathic hypersomnia (IH) on Dec 18, 2025.The trial is double-blind, placebo-controlled and measures the primary endpoint of change in Epworth Sleepiness Scale (ESS) at Week 14. Data are expected in Q2 2026. REVITALYZ includes participants switching from immediate-release oxybates and those not currently taking oxybates. ClinicalTrials.gov identifier: NCT06525077.

#AVDL Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia

www.stocktitan.net/news/AVDL/avadel-pharmac...

Announcement relating to despatch of Rule 15 proposal NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

#AVDL Announcement relating to despatch of Rule 15 proposal

www.stocktitan.net/news/AVDL/announcement-r...

Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Exercise Their Rights Halper Sadeh LLC has announced it is investigating potential shareholder rights violations regarding SEMR, AVDL, CADE, and DENN. Immediate contact is encouraged.

Halper Sadeh LLC Encourages SEMR, AVDL, CADE, DENN Shareholders to Exercise Their Rights #USA #New_York #Halper_Sadeh #AVDL #SEMR

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc Alkermes (Nasdaq: ALKS) agreed to increase its recommended offer to acquire Avadel (Nasdaq: AVDL) to up to $22.50 per share — consisting of $21.00 cash plus one non-transferable contingent value right (CVR) payable up to $1.50 if final FDA approval for LUMRYZ for idiopathic hypersomnia in adults is achieved by the end of 2028.The Increased Offer values Avadel at up to approximately $2.37 billion. The Amended Agreement was approved by both boards and the transaction remains expected to close in Q1 2026, subject to customary conditions and an extended End Date. J.P. Morgan provided fully committed financing for Alkermes.

#ALKS #AVDL Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

www.stocktitan.net/news/ALKS/alkermes-plc-a...

Avadel Receives Unsolicited Proposal from Lundbeck Avadel (Nasdaq: AVDL) said it received an unsolicited proposal from H. Lundbeck A/S to acquire Avadel for up to $23.00 per share—$21.00 cash at closing plus a non-transferable CVR worth up to $2.00 tied to U.S. net sales milestones for LUMRYZ and valiloxybate by 2027 and 2030. Avadel noted the Lundbeck Proposal is subject to shareholder and regulatory approvals and closing conditions.The Avadel Board determined in good faith the Lundbeck Proposal would reasonably be expected to result in a Company Superior Proposal under its agreement with Alkermes, permitting discussions but not terminating the Alkermes transaction (up to $20.00 per share).

#AVDL Avadel Receives Unsolicited Proposal from Lundbeck

www.stocktitan.net/news/AVDL/avadel-receive...

FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION (a) Full

#AVDL FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc

www.stocktitan.net/news/AVDL/form-8-1-a-b-a...

Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update – Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals,

#AVDL Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/AVDL/avadel-pharmac...

Halper Sadeh LLC Urges Shareholders of AVDL, MBCN, FMNB to Assert Their Legal Rights Halper Sadeh LLC, a leading investor rights law firm, calls on shareholders of Avadel, Middlefield, and Farmers to assert their rights amid potential legal violations.

Halper Sadeh LLC Urges Shareholders of AVDL, MBCN, FMNB to Assert Their Legal Rights #United_States #New_York #Halper_Sadeh_LLC #AVDL #MBCN

Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all litigation with Jazz Pharmaceuticals Inc. (“Jazz”). Under the primary terms of the

#AVDL Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement

www.stocktitan.net/news/AVDL/avadel-pharmac...

Salt-Free Sleep Drug Deal: Avadel Pharma Expands Portfolio with $20M Valiloxybate License for Narcolepsy Avadel gains global rights to valiloxybate, a once-nightly salt-free oxybate for narcolepsy and hypersomnia. Initial PK study in Q4 2025, pivotal trial H2 2026. Includes milestone payments and royalties.

#AVDL Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

www.stocktitan.net/news/AVDL/avadel-pharmac...

A trans girl in a full Crinklz Fairytale diaper

A trans girl in a full Crinklz Fairytale diaper

Mnfff... full...

#AVDL #MessyDiaper #DiaperGirl

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance Avadel Pharmaceuticals (NASDAQ:AVDL) reported strong Q2 2025 financial results, with LUMRYZ™ generating $68.1 million in net revenue, marking a 64% increase year-over-year. The company achieved its first quarterly net income of $9.7 million ($0.10 per share) since LUMRYZ's 2023 launch.Key highlights include 3,100 patients on LUMRYZ as of June 30, 2025 (63% YoY increase), and raised 2025 revenue guidance to $265-275 million. The company received FDA Orphan Drug Designation for LUMRYZ in Idiopathic Hypersomnia (IH) and expects to complete enrollment in the Phase 3 REVITALYZ™ study by end of 2025.The company's cash position strengthened to $81.5 million, with positive cash flow and a $15.0 million increase from Q1 2025.

#AVDL Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

www.stocktitan.net/news/AVDL/avadel-pharmac...

Major Victory: Court Backs LUMRYZ as Only Once-Nightly Narcolepsy Drug Against Jazz Challenge Unanimous appeals court decision validates FDA approval of LUMRYZ, securing its position as the sole once-at-bedtime narcolepsy treatment. See full ruling details.

#AVDL Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

www.stocktitan.net/news/AVDL/avadel-pharmac...

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance Avadel Pharmaceuticals (AVDL) reported strong Q1 2025 financial results and raised its guidance. The company generated $52.5 million in net revenue from LUMRYZ sales, marking a 93% increase year-over-year. Patient count reached 2,800 as of March 31, 2025, adding 300 new patients in Q1 and showing a 100% increase from Q1 2024. Avadel raised its 2025 guidance, now expecting $255-265 million in net product revenue and $30-40 million in cash flow. The Federal Circuit ruled in Avadel's favor, allowing the company to pursue FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH). The Phase 3 REVITALYZ study for IH is on track to complete enrollment by end of 2025. The company's Q1 net loss improved to $4.9 million ($0.05 per share) compared to $27.3 million ($0.30 per share) in Q1 2024.

#AVDL Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

www.stocktitan.net/news/AVDL/avadel-pharmac...

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction The United States Court of Appeals for the Federal Circuit has ruled in Avadel Pharmaceuticals' (NASDAQ: AVDL) favor, overturning key portions of a Delaware Court injunction regarding LUMRYZ™. The Federal Circuit vacated restrictions that previously prevented Avadel from seeking FDA approval for LUMRYZ beyond narcolepsy treatment. The ruling also lifts prohibitions on conducting new clinical trials and offering open-label extensions to trial participants.The company's REVITALYZ™ Phase 3 trial for Idiopathic Hypersomnia (IH) remains on schedule, with patient enrollment expected to complete by end of 2025. This double-blind, placebo-controlled study will evaluate LUMRYZ's efficacy and safety in approximately 150 adult IH patients, including those switching from immediate-release oxybates and new participants.

#AVDL Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

www.stocktitan.net/news/AVDL/avadel-pharmac...

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference Avadel Pharmaceuticals (AVDL) provided updates at the Needham Virtual Healthcare Conference, highlighting positive Q1 2025 metrics for LUMRYZ™, their narcolepsy medication with billion-dollar peak sales potential. The company reported improvements in patient enrollments, starts, persistency rates, and net patients on therapy compared to Q4 2024.Key updates include: The REVITALYZ™ Phase 3 trial for LUMRYZ in Idiopathic Hypersomnia remains on schedule for enrollment completion in H2 2025. Avadel has filed four patent infringement lawsuits against Jazz Pharmaceuticals in 2025 regarding Xywav product usage. The company expects to achieve sustainable positive cash flow in 2025.Addressing U.S. tariff policy concerns, Avadel detailed its robust supply chain for LUMRYZ, featuring dual FDA-approved U.S.-based manufacturers for the sodium oxybate API, U.S. and European manufacturing capabilities for the finished product, and U.S.-based primary packaging operations.

#AVDL Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

www.stocktitan.net/news/AVDL/avadel-pharmac...

Breakthrough Research Shows Narcolepsy Patients See Results in Just 2 Weeks with New Treatment Latest CNS Drugs publications reveal key insights on LUMRYZ's rapid efficacy and practical advantages in narcolepsy treatment. Full analysis inside.

#AVDL Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians

www.stocktitan.net/news/AVDL/avadel-announc...

LUMRYZ Sales Surge 158% as Avadel Pharmaceuticals Eyes Cash Flow Positive 2025 Q4 LUMRYZ sales hit $50.4M with significant net loss reduction. Company projects $240-260M revenue and positive cash flow for 2025 while expanding pediatric approval.

#AVDL Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/AVDL/avadel-pharmac...

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3 Avadel Pharmaceuticals (Nasdaq: AVDL) announced it will host a conference call and live webcast on March 3, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results, along with providing a corporate update. The webcast will be accessible through the company's investor relations website section, and a replay will be available for 90 days afterward. Interested participants are advised to register for the conference call at least 10 minutes before it begins.

#AVDL Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

www.stocktitan.net/news/AVDL/avadel-pharmac...

Avadel's LUMRYZ Narcolepsy Drug Hits $50M in Q4, Patient Base Surges 275% as Growth Accelerates Avadel Pharmaceuticals reports LUMRYZ Q4 revenue of $50M, with 2,500 patients now on therapy. Company projects strong 2025 outlook with $240-260M revenue target and expanding market share.

#AVDL Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

www.stocktitan.net/news/AVDL/avadel-announc...

Avadel Pharmaceuticals Schedules Q4 & Full Year 2024 Financial Results Conference Call Avadel Pharmaceuticals will host a conference call and webcast on January 8, 2025, to discuss Q4 and full-year 2024 preliminary results and provide corporate updates.

#AVDL Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8

www.stocktitan.net/news/AVDL/avadel-pharmac...

JUST IN: ( NASDAQ: #AVDL ) Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #AVDL ) Outperform Recommendation Issued On AVDL By Oppenheimer

#StockMarket #News

NEWS: ( NASDAQ: #AVDL ) Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation

#StockMarket #News

Soggy squishy paw-print lacking diaper on this big adult fox

Who's a soggy fox?

(It's me, I'm the soggy fox)
#avdl #diapers #wetdiaper

NEWS: ( NASDAQ: #AVDL ) Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ(TM) (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

#StockMarket #News

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BDTX, #U, #RAIL, #AVDL, #VKTX

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AEP, #TPX, #UAA, #IOVA, #AVDL

#OptionFlow #OptionsTrading #Trading